SITABASE D
Description
- Fixed-dose combination of Dapagliflozin 10 mg (SGLT2 inhibitor) and Sitagliptin 100 mg (DPP-4 inhibitor).
- Dual action: lowers blood glucose by increasing urinary glucose excretion and enhancing insulin secretion.
- Supports weight management through calorie loss in urine.
- Low risk of hypoglycemia when used appropriately.
- Convenient once-daily oral dosing for improved patient compliance.
- May provide cardiovascular and kidney protection benefits.
- Suitable as monotherapy or in combination with other antidiabetic agents under medical supervision.
Composition
DAPAGLIFLOZINE-10 MG, SITAGLIPTIN-100 MG
Benefits
SITABASE D provides comprehensive glycemic control by combining the benefits of both SGLT2 inhibition and DPP-4 inhibition. This combination helps reduce fasting and postprandial blood glucose levels, supports weight loss through glucose excretion, and improves insulin response without significant risk of hypoglycemia. Additionally, Dapagliflozin offers cardiovascular and renal protective effects, making SITABASE D an excellent therapeutic choice for patients with type 2 diabetes seeking improved metabolic and organ protection.
Introduction
SITABASE D is a combination oral medication containing Dapagliflozin 10 mg and Sitagliptin 100 mg, designed to improve blood sugar control in adults with type 2 diabetes mellitus. Dapagliflozin belongs to the class of SGLT2 inhibitors, which work by promoting the excretion of excess glucose through the urine, while Sitagliptin, a DPP-4 inhibitor, enhances insulin secretion and decreases glucagon levels in a glucose-dependent manner. Together, this dual mechanism addresses hyperglycemia through complementary pathways, offering an effective and convenient option for managing type 2 diabetes.
